Recognition and handling of discordant negative human epidermal growth factor receptor 2 classification by oncotype DX in patients with breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 26, 2012, Pages 3313-3314

  Christgen, Matthias ^a   Harbeck, Nadia ^b,c   Gluz, Oleg ^c   Nitz, Ulrike ^c   Kreipe, Hans H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c West German Study Group   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; MUCIN;

BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; FEMALE; HUMANS; QUALITY ASSURANCE, HEALTH CARE; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84866526626     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.1990     Document Type: Letter

References (4)

1. Dabbs DJ, Klein ME, Mohsin SK, et al: High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: An independent quality assurance study. J Clin Oncol 29:4279-4285, 2011
2. Degenhardt T, Gluz O, Kreipe HH, et al: Prospective comparison of recurrence score, uPA/PAI-1, central grade and molecular classification in early breast cancer: Interim results from the WSG-Plan B trial. J Clin Oncol 29:653s, 2011 (suppl 15; abstr 10594)
3. Schmitt M, Harbeck N, Brünner N, et al: Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 11:617-634, 2011
4. Lehmann-Che J, Amira-Bouhidel F, Turpin E, et al: Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches. Br J Cancer 104:1739-1746, 2011